Drug intelligence / Profile preview

Zhen-Qi-Jie-Du Granules II

Development stage: Preclinical
Lead developer: Jiangsu Famous Medical Technology
Administration: Oral

Overview

Zhen-Qi-Jie-Du Granules II is a Traditional Chinese Medicine (TCM) granule formulation being developed by Jiangsu Famous Medical Technology. It is currently being investigated in clinical trials as an adjuvant therapy combined with standard chemotherapy for patients with advanced, unresectable stage IV microsatellite-stable (MSS) colorectal cancer. Administered orally, the formulation is designed to provide synergistic therapeutic benefits, improve disease control, and alleviate chemotherapy-induced side effects such as fatigue and myelosuppression. The clinical development is being conducted in collaboration with institutions like the Jiangsu Province Hospital of Chinese Medicine.

Other names: Zhen-Qi-Jie-Du Granules Formula-II

Beyond the preview

Go deeper on Zhen-Qi-Jie-Du Granules II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhen-Qi-Jie-Du Granules II.